ArticleJournal of the National Cancer Institute2026
Menopausal hormone therapy and risk of liver cancer in a Swedish population-based cohort study.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Menopausal hormone therapy and primary liver cancer: long-term follow-up of the women's health initiative randomized trials.British journal of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPrevious studies have suggested a potential role of sex hormones in the development of liver cancer. This study aimed to examine whether menopausal hormone therapy (MHT) is associated with a decreased risk of liver cancer by histological type.
methodsThis Swedish population-based cohort study included 217 878 women who received MHT in 2006 to 2023 and an age-matched comparison group of 1 089 390 women who did not receive MHT. Cox regression assessed the associations between use of MHT and the risk of 2 main subtypes of liver cancer, that is, hepatocellular carcinoma and intrahepatic cholangiocarcinoma, with adjustment for smoking- and alcohol-related diagnoses, non-alcoholic fatty liver disease, diabetes or obesity, hysterectomy, use of non-steroidal anti-inflammatory drugs or aspirin, and use of statins.
resultsMHT users had a decreased risk of hepatocellular carcinoma (hazard ratio [HR] = 0.46, 95% confidence interval [CI] = 0.30 to 0.72). Decreased HRs of hepatocellular carcinoma were indicated both in users of estrogen only (HR = 0.42, 95% CI = 0.21 to 0.86) and estrogen combined with progestogen (HR = 0.49, 95% CI = 0.28 to 0.85). The risk reduction in hepatocellular carcinoma was apparently more pronounced in users aged 60 years or older (HR = 0.37, 95% CI = 0.19 to 0.75). The use of MHT was not associated with the risk of intrahepatic cholangiocarcinoma (HR = 0.99, 95% CI = 0.72 to 1.36).
conclusionsMHT in women may decrease the risk of hepatocellular carcinoma, but not intrahepatic cholangiocarcinoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.